Trial Profile

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis C (FOURward Study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Asunaprevir/becabluvir/daclatasvir (Primary) ; Peginterferon alfa-2a; Ribavirin; Sofosbuvir
Indications Hepatitis C
Focus Adverse reactions; Therapeutic Use
Acronyms FOURward
Sponsors Bristol-Myers Squibb

Most Recent Events

07 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
26 Feb 2015 Planned End Date changed from 1 Apr 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov
30 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com